Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution

Sonoda,Hiromichi; Mekata,Eiji; Shimizu,Tomoharu; Endo,Yoshihiro; Tani,Tohru

doi:10.3892/ol.2013.1171

April 2013 Volume 5 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April 2013 Volume 5 Issue 4

Full Size Image

Article

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution

Authors:
- Hiromichi Sonoda
- Eiji Mekata
- Tomoharu Shimizu
- Yoshihiro Endo
- Tohru Tani
View Affiliations / Copyright

Affiliations: Department of Surgery, Shiga University of Medical Science, Shiga 520-2192, Japan
Pages: 1331-1334
|
Published online on: February 1, 2013

https://doi.org/10.3892/ol.2013.1171
Expand metrics +

Abstract

Panitumumab (Pmab) is generally considered to be ineffective after the failure of cetuximab (Cmab) therapy in metastatic colorectal cancer (mCRC) patients. However, a few studies have demonstrated that Pmab is an effective treatment for disease progression following Cmab-based regimens in the USA. In the present study, we evaluated the safety and efficacy of Pmab therapy following the failure of Cmab therapy in Japanese patients with mCRC. We performed a retrospective review of the treatment of 16 mCRC patients who tolerated Pmab with clinical benefits after the failure of Cmab therapy between August 2010 and September 2011 at Shiga University of Medical Science. Fourteen of the 16 patients were administered standard Pmab monotherapy (6 mg/kg) intravenously every 2 weeks and the remaining two patients received Pmab with mFOLFOX6 intravenously every 2 weeks. All patients received Pmab chemotherapy until the occurrence of disease progression. Partial radiographic responses (PR) were observed in 2 of the 16 patients and stable disease (SD) was observed in 5 patients. Nine patients had evidence of progressive disease (PD). According to the KRAS status, 7 of the 13 (53.8%) patients who had wild‑type KRAS achieved a high disease control rate (PR + SD). The median progression-free survival (PFS) and overall survival (OS) in the wild-type KRAS patients was 96 and 245 days, respectively. Pmab may be an alternative treatment strategy for Japanese patients with mCRC who have experienced failure with standard Cmab-based therapeutic regimens.

View Figures

View References

1	Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
3	Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C and Jensen BV: Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol. 46:697–701. 2007. View Article : Google Scholar : PubMed/NCBI
4	Cohenuram M and Saif MW: Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 18:7–15. 2007. View Article : Google Scholar : PubMed/NCBI
5	Saif MW, Kaley K, Chu E and Copur MS: Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clinical Colorectal Cancer. 9:315–318. 2010. View Article : Google Scholar : PubMed/NCBI
6	Power DG, Shah MA, Asmis TR, Garcia JJ and Kemeny NE: Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs. 28:353–360. 2010. View Article : Google Scholar : PubMed/NCBI
7	van Persijn van Meerten EL, Gelderblom H and Bloem JL: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 20:1456–1467. 2010.PubMed/NCBI
8	Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI
9	Van Cutsem E: First-line treatment: approaches with cytotoxic and biologic agents. New Treatment Strategies for Metastatic Colorectal Cancer. Chu E: CMP Healthcare Media; Manhasset, NY: pp. 21–46. 2008
10	Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol. 33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jean GW and Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 28:742–754. 2008. View Article : Google Scholar : PubMed/NCBI
12	Cmelak AJ, Lordick F, Borner M, Goldberg RM and Saif MW: Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston Park). 23(Suppl 1): 18–25. 2009.PubMed/NCBI
13	Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 18:221–223. 2012. View Article : Google Scholar : PubMed/NCBI
14	Freeman D, Sun J, Bass R, et al: Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol. 26May 20;(Suppl): 145362008.
15	Leahy DJ: A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell. 13:291–293. 2008. View Article : Google Scholar : PubMed/NCBI
16	Schmiedel J, Blaukat A, Li S, Knöchel T and Ferguson KM: Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 13:365–373. 2008. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles